Ronald Bosch

CD4/CD8 Ratio and Cancer Risk among Adults with HIV.

Castilho JL, Bian A, Jenkins CA, Shepherd BE, Sigel K, Gill MJ, Kitahata MM, Silverberg MJ, Mayor AM, Coburn SB, Wiley D, Achenbach CJ, Marconi VC, Bosch RJ, Horberg MA, Rabkin CS, Napravnik S, Novak RM, Mathews WC, Thorne JE, Sun J, Althoff KN, Moore RD, Sterling TR, Sudenga SL.

J Natl Cancer Inst. 2022 Mar 16. PMID: 35292820

Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.

Li JZ, Aga E, Bosch RJ, Pilkinton M, Kroon E, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Ananworanich J, Coombs R, Mellors JW, Landay AL, Macatangay B, Deeks S, Gandhi RT, Smith DM.

Clin Infect Dis. 2022 03 09. 74(5):865-870. PMID: 34117753

Reply to Bottanelli et al.

Cyktor JC, Bosch RJ, Mar H, Macatangay BJ, Collier AC, Hogg E, Godfrey C, Eron JJ, McMahon DK, Mellors JW, Gandhi RT.

J Infect Dis. 2022 Feb 26. PMID: 35381084

Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial).

Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, Morse GD, Squires KE, Howell BJ, Wu G, Hosey L, Sieg S, Ehui L, Giguel F, Coxen K, Dobrowlski C, Gandhi M, Deeks S, Chomont N, Connick E, Godfrey C, Karn J, Kuritzkes DR, Bosch RJ, Gandhi RT.

Clin Infect Dis. 2022 Feb 17. PMID: 35176755

Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients.

Ivison GT, Vendrame E, Martínez-Colón GJ, Ranganath T, Vergara R, Zhao NQ, Martin MP, Bendall SC, Carrington M, Cyktor JC, McMahon DK, Eron J, Jones RB, Mellors JW, Bosch RJ, Gandhi RT, Holmes S, Blish CA.

Front Cell Infect Microbiol. 2022. 12:757846. PMID: 35223535

Associations between multiple measures of HIV-1 persistence on suppressive antiretroviral therapy.

Bosch RJ, Gandhi RT, Mar H, Eron JJ, Cyktor JC, McMahon DK, Mellors JW.

J Infect Dis. 2022 Feb 04. PMID: 35137129

Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.

Fajnzylber J, Sharaf R, Hutchinson JN, Aga E, Bosch RJ, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest DJ, Margolis D, Sneller MC, Little SJ, Gulick RM, Mellors JW, Gandhi RT, Schooley RT, Henry K, Tebas P, Deeks S, Chun TW, Collier AC, Hecht FM, Li JZ.

AIDS. 2021 11 01. 35(13):2225-2227. PMID: 34127579

Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV.

Gay CL, Bosch RJ, McKhann A, Moseley KF, Wimbish CL, Hendrickx SM, Messer M, Furlong M, Campbell DM, Jennings C, Benson C, Overton ET, Macatangay BJC, Kuritzkes DR, Miller E, Tressler R, Eron JJ, Hardy WD.

J Acquir Immune Defic Syndr. 2021 08 15. 87(5):e234-e236. PMID: 33929394

Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study.

Edwards JK, Cole SR, Breger TL, Rudolph JE, Filiatreau LM, Buchacz K, Humes E, Rebeiro PF, D'Souza G, Gill MJ, Silverberg MJ, Mathews WC, Horberg MA, Thorne J, Hall HI, Justice A, Marconi VC, Lima VD, Bosch RJ, Sterling TR, Althoff KN, Moore RD, Saag M, Eron JJ.

Ann Intern Med. 2021 09. 174(9):1197-1206. PMID: 34224262

Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.

Zheng L, Tierney C, Bosch RJ.

Curr HIV/AIDS Rep. 2021 10. 18(5):475-482. PMID: 34213731